F
Filip K. Knop
Researcher at University of Copenhagen
Publications - 523
Citations - 17834
Filip K. Knop is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Type 2 diabetes & Diabetes mellitus. The author has an hindex of 61, co-authored 437 publications receiving 13614 citations. Previous affiliations of Filip K. Knop include Copenhagen University Hospital & Victor Chang Cardiac Research Institute.
Papers
More filters
Journal ArticleDOI
Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus.
TL;DR: Attenuated and delayed glucagon suppression in patients with type 2 diabetes occurs after oral ingestion of glucose, while isoglycaemic i.v. administration of glucose results in normal suppression of glucagon, and it is suggested that this phenomenon contributes both to the glucose intolerance and to the reduced incretin effect observed in patients.
Journal ArticleDOI
Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Heidi Storgaard,Lise Lotte Gluud,Cathy Bennett,Magnus F. Grøndahl,Mikkel B. Christensen,Filip K. Knop,Tina Vilsbøll +6 more
TL;DR: This review includes a large number of patients with type 2 diabetes and found that SGLT2-i reduces HbA1c with a notable increased risk in non-serious adverse events and downgraded the evidence to ‘low quality’ due to variability and evidence of publication bias.
Journal ArticleDOI
Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?
Nicolai J. Wewer Albrechtsen,Bolette Hartmann,Simon Veedfald,Johanne Agerlin Windeløv,Astrid Plamboeck,Kirstine N. Bojsen-Møller,Thomas Idorn,Bo Feldt-Rasmussen,Filip K. Knop,Tina Vilsbøll,Sten Madsbad,Carolyn F. Deacon,Jens J. Holst +12 more
TL;DR: Comparing glucagon measurements in clinical samples with an established glucagon RIA indicated that the apparent hyperglucagonaemia is not caused by fully processed intact glucagon, and sensitive C-terminal glucagon RIAs are accurate.
Journal ArticleDOI
Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease.
Lili Niu,Lili Niu,Philipp E. Geyer,Philipp E. Geyer,Nicolai J. Wewer Albrechtsen,Lise Lotte Gluud,Alberto Santos,Sophia Doll,Sophia Doll,Peter V. Treit,Jens J. Holst,Filip K. Knop,Filip K. Knop,Tina Vilsbøll,Tina Vilsbøll,Anders Ellekær Junker,Anders Ellekær Junker,Stephan Sachs,Kerstin Stemmer,Timo D. Müller,Matthias H. Tschöp,Susanna M. Hofmann,Matthias Mann,Matthias Mann +23 more
TL;DR: Plasma proteome profiling can identify potential biomarkers and drug targets in liver disease and strongly associated DPP4, ANPEP, TGFBI, PIGR, and APOE with NAFLD and cirrhosis.
Journal ArticleDOI
Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity
Filip K. Knop,Kasper Aaboe,Tina Vilsbøll,Anders Vølund,J. J. Holst,Thure Krarup,Sten Madsbad +6 more
TL;DR: People with type 2 diabetes mellitus are characterized by reduced incretin effect and inappropriate glucagon levels, and α and β‐cell responses to oral glucose tolerance test and isoglycaemic intravenous glucose infusion in lean and obese persons with T2DM or normal glucose tolerance (NGT) are evaluated to elucidate the impact of obesity.